Halozyme CEO exercises options, sells 1,923 shares
Halozyme Therapeutics President and CEO Helen Torley exercised stock options for 1,923 shares of common stock at $12.07 per share and immediately sold the same 1,923 shares in open‑market transactions at prices around $79–$80 per share.
Rhea-AI Filing Summary
Halozyme Therapeutics President and CEO Helen Torley exercised stock options for 1,923 shares of common stock at $12.07 per share and immediately sold the same 1,923 shares in open‑market transactions at prices around $79–$80 per share. These trades were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on March 21, 2025, and involved options that were due to expire in February 2027. After these transactions, Torley directly holds 767,780 shares of Halozyme common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,923 shares ($130K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
1,923 shs ($153K)
Approx. gross sale proceeds
$153K
Approx. exercise cost
$23K
Approx. pre-tax spread
$130K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 1,923 | $12.07 | $23K |
| Exercise | Common Stock | 1,923 | $12.07 | $23K |
| Sale | Common Stock | 888 | $79.276 | $70K |
| Sale | Common Stock | 1,035 | $80.187 | $83K |
Holdings After Transaction:
Option to Purchase Common Stock — 0 contracts (Direct);
Common Stock — 767,780 shares (Direct)
Footnotes (4)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.710 to $79.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $79.710 to $80.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
Key Figures
Shares sold: 1,923 shares
Sale prices tranche 1: $79.276/share
Sale prices tranche 2: $80.187/share
+5 more
8 metrics
Shares sold
1,923 shares
Total common shares sold in open-market transactions on July 8, 2026
Sale prices tranche 1
$79.276/share
Weighted average price for 888 shares sold; range $78.710–$79.700
Sale prices tranche 2
$80.187/share
Weighted average price for 1,035 shares sold; range $79.710–$80.490
Option exercise price
$12.07/share
Exercise price for 1,923 stock option shares converted to common
Post-transaction holdings
767,780 shares
Common shares directly owned by Helen Torley after transactions
Trading plan adoption date
March 21, 2025
Date Rule 10b5-1 plan governing these trades was adopted
Option grant date
February 22, 2017
Grant date of ten-year stock options exercised in this Form 4
Option expiration
February 2027
Expiration timing for the exercised stock options
Key Terms
Rule 10b5-1, weighted average sales price, Option to Purchase Common Stock, stock options, +2 more
6 terms
Rule 10b5-1 regulatory
"were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average sales price financial
"Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.710 to $79.700."
Option to Purchase Common Stock financial
"security_title": "Option to Purchase Common Stock""
stock options financial
"shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
ten-year term financial
"exercise of stock options with a ten-year term expiring in February 2027"
vesting financial
"exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did HALO CEO Helen Torley report on this Form 4?
Helen Torley reported exercising options for 1,923 Halozyme shares at $12.07 each, then selling all 1,923 shares in open‑market trades around $79–$80 per share. The transactions were compensation-related and disclosed as routine Form 4 activity.
Did the HALO CEO’s stock sale come from exercised options?
Yes. The filing states the 1,923 Halozyme shares sold were acquired through exercising stock options with a ten‑year term and an exercise price of $12.07 per share. Those options were originally granted on February 22, 2017 and were approaching their February 2027 expiration.
What were the key terms of the HALO CEO’s exercised stock options?
The options covered 1,923 Halozyme shares at an exercise price of $12.07 per share and had a ten‑year term expiring in February 2027. They were granted on February 22, 2017, vesting over four years, with 25% after 12 months and monthly vesting thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
